

106TH CONGRESS  
2D SESSION

# S. 3107

To amend title XVIII of the Social Security Act to provide coverage of outpatient prescription drugs under the Medicare Program.

---

## IN THE SENATE OF THE UNITED STATES

SEPTEMBER 26 (legislative day, SEPTEMBER 22), 2000

Mr. GRAHAM (for himself, Mr. BRYAN, Mr. KENNEDY, Mr. ROCKEFELLER, and Mr. ROBB) introduced the following bill; which was read the first time

---

## A BILL

To amend title XVIII of the Social Security Act to provide coverage of outpatient prescription drugs under the Medicare Program.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

### 3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) SHORT TITLE.—This Act may be cited as the  
5 “Medicare Prescription Drug Coverage Act of 2000”.

6 (b) TABLE OF CONTENTS.—The table of contents of  
7 this Act is as follows:

Sec. 1. Short title; table of contents.

Sec. 2. Medicare outpatient prescription drug benefit program.

“PART D—OUTPATIENT PRESCRIPTION DRUG BENEFIT PROGRAM

“Sec. 1860. Definitions.

“SUBPART 1—ESTABLISHMENT OF OUTPATIENT PRESCRIPTION DRUG  
BENEFIT PROGRAM

“Sec. 1860A. Establishment of outpatient prescription drug benefit program.

“Sec. 1860B. Enrollment.

“Sec. 1860C. Providing information to beneficiaries.

“Sec. 1860D. Premiums.

“Sec. 1860E. Cost-sharing.

“Sec. 1860F. Selection of entities to provide outpatient drug benefit.

“Sec. 1860G. Conditions for awarding contract.

“Sec. 1860H. Payments.

“Sec. 1860I. Employer incentive program for employment-based retiree drug coverage.

“Sec. 1860J. Appropriations.

“SUBPART 2—MEDICARE PHARMACY AND THERAPEUTICS (P&T) ADVISORY  
COMMITTEE

“Sec. 1860M. Medicare Pharmacy and Therapeutics (P&T) Advisory Committee.”.

Sec. 3. Part D benefits under Medicare+Choice plans.

Sec. 4. Exclusion of part D costs from determination of part B monthly premium.

Sec. 5. Additional assistance for low-income beneficiaries.

Sec. 6. Medigap revisions.

Sec. 7. HHS studies and report to Congress.

Sec. 8. Appropriations.

**1 SEC. 2. MEDICARE OUTPATIENT PRESCRIPTION DRUG BEN-**  
**2 EFIT PROGRAM.**

**3 (a) ESTABLISHMENT.**—Title XVIII of the Social Se-  
**4 curity Act (42 U.S.C. 1395 et seq.) is amended by redesi-**  
**5 nating part D as part E and by inserting after part C**  
**6 the following new part:**

**7 “PART D—OUTPATIENT PRESCRIPTION DRUG BENEFIT**  
**8 PROGRAM**

**9 “DEFINITIONS**

**10 “SEC. 1860. In this part:**

**11 “(1) COVERED OUTPATIENT DRUG.—**

1           “(A) IN GENERAL.—Except as provided in  
2           subparagraph (B), the term ‘covered outpatient  
3           drug’ means any of the following products:

4                   “(i) A drug which may be dispensed  
5                   only upon prescription, and—

6                           “(I) which is approved for safety  
7                           and effectiveness as a prescription  
8                           drug under section 505 of the Federal  
9                           Food, Drug, and Cosmetic Act;

10                           “(II)(aa) which was commercially  
11                           used or sold in the United States be-  
12                           fore the date of enactment of the  
13                           Drug Amendments of 1962 or which  
14                           is identical, similar, or related (within  
15                           the meaning of section 310.6(b)(1) of  
16                           title 21 of the Code of Federal Regu-  
17                           lations) to such a drug, and (bb)  
18                           which has not been the subject of a  
19                           final determination by the Secretary  
20                           that it is a ‘new drug’ (within the  
21                           meaning of section 201(p) of the Fed-  
22                           eral Food, Drug, and Cosmetic Act)  
23                           or an action brought by the Secretary  
24                           under section 301, 302(a), or 304(a)

1 of such Act to enforce section 502(f)  
2 or 505(a) of such Act; or

3 “(III)(aa) which is described in  
4 section 107(c)(3) of the Drug Amend-  
5 ments of 1962 and for which the Sec-  
6 retary has determined there is a com-  
7 pelling justification for its medical  
8 need, or is identical, similar, or re-  
9 lated (within the meaning of section  
10 310.6(b)(1) of title 21 of the Code of  
11 Federal Regulations) to such a drug,  
12 and (bb) for which the Secretary has  
13 not issued a notice of an opportunity  
14 for a hearing under section 505(e) of  
15 the Federal Food, Drug, and Cos-  
16 metic Act on a proposed order of the  
17 Secretary to withdraw approval of an  
18 application for such drug under such  
19 section because the Secretary has de-  
20 termined that the drug is less than ef-  
21 fective for all conditions of use pre-  
22 scribed, recommended, or suggested in  
23 its labeling.

24 “(ii) A biological product which—

1                   “(I) may only be dispensed upon  
2                   prescription;

3                   “(II) is licensed under section  
4                   351 of the Public Health Service Act;  
5                   and

6                   “(III) is produced at an estab-  
7                   lishment licensed under such section  
8                   to produce such product.

9                   “(iii) Insulin approved under appro-  
10                  priate Federal law, including needles, sy-  
11                  ringes, and disposable pumps for the ad-  
12                  ministration of such insulin.

13                  “(iv) A prescribed drug or biological  
14                  product that would meet the requirements  
15                  of clause (i) or (ii) but that it is available  
16                  over-the-counter in addition to being avail-  
17                  able upon prescription.

18                  “(B) EXCLUSION.—The term ‘covered out-  
19                  patient drug’ does not include any product—

20                  “(i) except as provided in subpara-  
21                  graph (A)(iv), which may be distributed to  
22                  individuals without a prescription;

23                  “(ii) that is covered under part A or  
24                  B (unless coverage of such product is not

1 available because benefits under part A or  
 2 B have been exhausted); or

3 “(iii) except for agents used to pro-  
 4 mote smoking cessation, for which cov-  
 5 erage may be excluded or restricted under  
 6 section 1927(d)(2).

7 “(2) ELIGIBLE BENEFICIARY.—The term ‘eligi-  
 8 ble beneficiary’ means an individual that is entitled  
 9 to benefits under part A or enrolled under part B.

10 “(3) ELIGIBLE ENTITY.—The term ‘eligible en-  
 11 tity’ means any entity that the Secretary determines  
 12 to be appropriate to provide eligible beneficiaries  
 13 with covered outpatient drugs under a contract en-  
 14 tered into under this part, including—

15 “(A) a pharmacy benefit management com-  
 16 pany;

17 “(B) a retail pharmacy delivery system;

18 “(C) a health plan or insurer;

19 “(D) a State (through mechanisms estab-  
 20 lished under a State plan under title XIX);

21 “(E) any other entity approved by the Sec-  
 22 retary; or

23 “(F) any combination of the entities de-  
 24 scribed in subparagraphs (A) through (E) if the  
 25 Secretary determines that such combination—

1 “(i) increases the scope or efficiency  
 2 of the provision of benefits under this part;  
 3 and

4 “(ii) is not anticompetitive.

5 “SUBPART 1—ESTABLISHMENT OF OUTPATIENT  
 6 PRESCRIPTION DRUG BENEFIT PROGRAM

7 “ESTABLISHMENT OF OUTPATIENT PRESCRIPTION DRUG  
 8 BENEFIT PROGRAM

9 “SEC. 1860A. (a) PROVISION OF BENEFIT.—Begin-  
 10 ning in 2002, the Secretary shall provide for an outpatient  
 11 prescription drug benefit program under which an eligible  
 12 beneficiary shall be provided covered outpatient drugs.

13 “(b) VOLUNTARY NATURE OF PROGRAM.—Nothing  
 14 in this part shall be construed as requiring an eligible ben-  
 15 eficiary to enroll in the program established under this  
 16 part.

17 “(c) SCOPE OF BENEFITS.—The program established  
 18 under this part shall provide for coverage of all therapeutic  
 19 classes of covered outpatient drugs.

20 “(d) FINANCING.—The costs of providing benefits  
 21 under this part shall be payable from the Federal Supple-  
 22 mentary Medical Insurance Trust Fund established under  
 23 section 1841.

24 “ENROLLMENT

25 “SEC. 1860B. (a) ENROLLMENT UNDER PART D.—

26 “(1) ESTABLISHMENT OF PROCESS.—

1           “(A) IN GENERAL.—The Secretary shall  
2           establish a process through which an eligible  
3           beneficiary (including an eligible beneficiary en-  
4           rolled in a Medicare+Choice plan offered by a  
5           Medicare+Choice organization) may make an  
6           election to enroll under this part. Such process  
7           shall be similar to the process for enrollment in  
8           part B under section 1837.

9           “(B) REQUIREMENT OF ENROLLMENT.—  
10          An eligible beneficiary must enroll under this  
11          part in order to be eligible to receive covered  
12          outpatient drugs under this title.

13          “(2) ENROLLMENT PROCEDURES.—

14               “(A) LATE ENROLLMENT PENALTY.—

15                   “(i) IN GENERAL.—Subject to the  
16                   succeeding provisions of this subparagraph,  
17                   in the case of an eligible beneficiary whose  
18                   coverage period under this part began pur-  
19                   suant to an enrollment after the bene-  
20                   ficiary’s initial enrollment period under  
21                   part B (determined pursuant to section  
22                   1837(d)) and not pursuant to the open en-  
23                   rollment period described in subparagraph  
24                   (B), the Secretary shall establish proce-  
25                   dures for increasing the amount of the



1 monthly premium under section 1860D ap-  
2 plicable to such beneficiary—

3 “(I) by an amount that is equal  
4 to 10 percent of such premium for  
5 each full 12-month period (in the  
6 same continuous period of eligibility)  
7 in which the eligible beneficiary could  
8 have been enrolled under this part but  
9 was not so enrolled; or

10 “(II) if determined appropriate  
11 by the Secretary, by an amount that  
12 the Secretary determines is actuarially  
13 sound for each such period.

14 “(ii) PERIODS TAKEN INTO AC-  
15 COUNT.—For purposes of calculating any  
16 12-month period under clause (i), there  
17 shall be taken into account—

18 “(I) the months which elapsed  
19 between the close of the eligible bene-  
20 ficiary’s initial enrollment period and  
21 the close of the enrollment period in  
22 which the beneficiary enrolled; and

23 “(II) in the case of an eligible  
24 beneficiary who reenrolls under this  
25 part, the months which elapsed be-

1           tween the date of termination of a  
2           previous coverage period and the close  
3           of the enrollment period in which the  
4           beneficiary reenrolled.

5           “(iii) PERIODS NOT TAKEN INTO AC-  
6           COUNT.—

7                       “(I) IN GENERAL.—For purposes  
8           of calculating any 12-month period  
9           under clause (i), subject to subclause  
10          (II), there shall not be taken into ac-  
11          count months for which the eligible  
12          beneficiary can demonstrate that the  
13          beneficiary was covered under a group  
14          health plan, including a qualified re-  
15          tiree prescription drug plan (as de-  
16          fined in section 1860I(e)(3)) for which  
17          an incentive payment was paid under  
18          section 1860I, that provides coverage  
19          of the cost of prescription drugs  
20          whose actuarial value (as defined by  
21          the Secretary) to the beneficiary  
22          equals or exceeds the actuarial value  
23          of the benefits provided to an indi-  
24          vidual enrolled in the outpatient pre-

1           scripture drug benefit program under  
2           this part.

3                   “(II) APPLICATION.—This clause  
4           shall only apply with respect to a cov-  
5           erage period the enrollment for which  
6           occurs before the end of the 60-day  
7           period that begins on the first day of  
8           the month which includes the date on  
9           which the plan terminates, ceases to  
10          provide, or reduces the value of the  
11          prescription drug coverage under such  
12          plan to below the value of the cov-  
13          erage provided under the program  
14          under this part.

15                   “(iv) PERIODS TREATED SEPA-  
16          RATELY.—Any increase in an eligible bene-  
17          ficiary’s monthly premium under clause (i)  
18          with respect to a particular continuous pe-  
19          riod of eligibility shall not be applicable  
20          with respect to any other continuous period  
21          of eligibility which the beneficiary may  
22          have.

23                   “(v) CONTINUOUS PERIOD OF ELIGI-  
24          BILITY.—

1                   “(I) IN GENERAL.—Subject to  
 2                   subclause (II), for purposes of this  
 3                   subparagraph, an eligible beneficiary’s  
 4                   ‘continuous period of eligibility’ is the  
 5                   period that begins with the first day  
 6                   on which the beneficiary is eligible to  
 7                   enroll under section 1836 and ends  
 8                   with the beneficiary’s death.

9                   “(II) SEPARATE PERIOD.—Any  
 10                  period during all of which an eligible  
 11                  beneficiary satisfied paragraph (1) of  
 12                  section 1836 and which terminated in  
 13                  or before the month preceding the  
 14                  month in which the beneficiary at-  
 15                  tained age 65 shall be a separate ‘con-  
 16                  tinuous period of eligibility’ with re-  
 17                  spect to the beneficiary (and each  
 18                  such period which terminates shall be  
 19                  deemed not to have existed for pur-  
 20                  poses of subsequently applying this  
 21                  subparagraph).

22                  “(B) OPEN ENROLLMENT PERIOD FOR  
 23                  CURRENT BENEFICIARIES IN WHICH LATE EN-  
 24                  ROLLMENT PROCEDURES DO NOT APPLY.—The  
 25                  Secretary shall establish an applicable period,

1 which shall begin on the date on which the Sec-  
 2 retary first begins to accept elections for enroll-  
 3 ment under this part, during which any eligible  
 4 beneficiary may enroll under this part without  
 5 the application of the late enrollment proce-  
 6 dures established under subparagraph (A)(i).

7 “(3) PERIOD OF COVERAGE.—

8 “(A) IN GENERAL.—Except as provided in  
 9 subparagraph (B), an eligible beneficiary’s cov-  
 10 erage under the program under this part shall  
 11 be effective for the period provided in section  
 12 1838, as if that section applied to the program  
 13 under this part.

14 “(B) OPEN ENROLLMENT.—An eligible  
 15 beneficiary who enrolls under the program  
 16 under this part pursuant to paragraph (2)(B)  
 17 shall be entitled to the benefits under this part  
 18 beginning on the first day of the month fol-  
 19 lowing the month in which such enrollment oc-  
 20 curs.

21 “(C) LIMITATION.—Coverage under this  
 22 part shall not begin prior to January 1, 2002.

23 “(4) PART D COVERAGE TERMINATED BY TER-  
 24 MINATION OF COVERAGE UNDER PARTS A AND B.—

1           “(A) IN GENERAL.—In addition to the  
 2           causes of termination specified in section 1838,  
 3           the Secretary shall terminate an individual’s  
 4           coverage under this part if the individual is no  
 5           longer enrolled in either part A or part B.

6           “(B) EFFECTIVE DATE.—The termination  
 7           described in subparagraph (A) shall be effective  
 8           on the effective date of termination of coverage  
 9           under part A or (if later) under part B.

10          “(b) ENROLLMENT WITH ELIGIBLE ENTITY.—

11           “(1) PROCESS.—

12           “(A) IN GENERAL.—The Secretary shall  
 13           establish a process through which an eligible  
 14           beneficiary who is enrolled under this part but  
 15           not enrolled in a Medicare+Choice plan offered  
 16           by a Medicare+Choice organization shall make  
 17           an annual election to enroll with any eligible en-  
 18           tity that has been awarded a contract under  
 19           this part and serves the geographic area in  
 20           which the beneficiary resides.

21           “(B) RULES.—In establishing the process  
 22           under subparagraph (A), the Secretary shall  
 23           use rules similar to the rules for enrollment and  
 24           disenrollment with a Medicare+Choice plan

1 under section 1851 (including special election  
2 periods under subsection (e)(4) of such section).

3 “(2) MEDICARE+CHOICE ENROLLEES.—An eli-  
4 gible beneficiary who is enrolled under this part and  
5 enrolled in a Medicare+Choice plan offered by a  
6 Medicare+Choice organization shall receive coverage  
7 of covered outpatient drugs under this part through  
8 such plan.

9 “(c) FIRST ENROLLMENT PERIOD.—The processes  
10 developed under subsections (a) and (b) shall ensure that  
11 eligible beneficiaries are permitted to enroll under this  
12 part and with an eligible entity prior to January 1, 2002,  
13 in order to ensure that coverage under this part is effective  
14 as of such date.

15 “PROVIDING INFORMATION TO BENEFICIARIES

16 “SEC. 1860C. (a) ACTIVITIES.—

17 “(1) IN GENERAL.—The Secretary shall con-  
18 duct activities that are designed to broadly dissemi-  
19 nate information to eligible beneficiaries (and pro-  
20 spective eligible beneficiaries) regarding the coverage  
21 provided under this part.

22 “(2) SPECIAL RULE FOR FIRST ENROLLMENT  
23 UNDER THE PROGRAM.—To the extent practicable,  
24 the activities described in paragraph (1) shall ensure  
25 that eligible beneficiaries are provided with such in-

1       formation at least 30 days prior to the first enroll-  
2       ment period described in section 1860B(c).

3       “(b) REQUIREMENTS.—

4               “(1) IN GENERAL.—The activities described in  
5       subsection (a) shall—

6                       “(A) be similar to the activities performed  
7       by the Secretary under section 1851(d);

8                       “(B) be coordinated with the activities per-  
9       formed by the Secretary under such section and  
10      under section 1804; and

11                      “(C) provide for the dissemination of infor-  
12      mation comparing the eligible entities that are  
13      available to eligible beneficiaries residing in an  
14      area under this part.

15               “(2) COMPARATIVE INFORMATION.—The com-  
16      parative information described in paragraph (1)(B)  
17      shall include the following:

18                      “(A) BENEFITS.—A comparison of the  
19      benefits provided by each eligible entity, includ-  
20      ing a comparison of the pharmacy networks  
21      used by each eligible entity and the formularies  
22      and appeals processes implemented by each en-  
23      tity.



1           “(B) QUALITY AND PERFORMANCE.—To  
 2           the extent available, the quality and perform-  
 3           ance of each eligible entity.

4           “(C) BENEFICIARY COSTS.—The cost-shar-  
 5           ing required of eligible beneficiaries enrolled in  
 6           each eligible entity.

7           “(D) CONSUMER SATISFACTION SUR-  
 8           VEYS.—To the extent available, the results of  
 9           consumer satisfaction surveys regarding each  
 10          eligible entity.

11          “(E) ADDITIONAL INFORMATION.—Such  
 12          additional information as the Secretary may  
 13          prescribe.

14          “(3) INFORMATION STANDARDS.—The Sec-  
 15          retary shall develop standards to ensure that the in-  
 16          formation provided to eligible beneficiaries under  
 17          this part is complete, accurate, and uniform.

18          “(c) USE OF MEDICARE CONSUMER COALITIONS TO  
 19          PROVIDE INFORMATION.—

20                 “(1) IN GENERAL.—The Secretary may con-  
 21                 tract with Medicare Consumer Coalitions to conduct  
 22                 the informational activities—

23                         “(A) under this section;

24                         “(B) under section 1851(d); and

25                         “(C) under section 1804.

1           “(2) SELECTION OF COALITIONS.—If the Sec-  
 2       retary determines the use of Medicare Consumer  
 3       Coalitions to be appropriate, the Secretary shall—

4           “(A) develop and disseminate, in such  
 5       areas as the Secretary determines appropriate,  
 6       a request for proposals for Medicare Consumer  
 7       Coalitions to contract with the Secretary in  
 8       order to conduct any of the informational ac-  
 9       tivities described in paragraph (1); and

10          “(B) select a proposal of a Medicare Con-  
 11       sumer Coalition to conduct the informational  
 12       activities in each such area, with a preference  
 13       for broad participation by organizations with  
 14       experience in providing information to bene-  
 15       ficiaries under this title.

16          “(3) PAYMENT TO MEDICARE CONSUMER COA-  
 17       LITIONS.—The Secretary shall make payments to  
 18       Medicare Consumer Coalitions contracting under  
 19       this subsection in such amounts and in such manner  
 20       as the Secretary determines appropriate.

21          “(4) AUTHORIZATION OF APPROPRIATIONS.—  
 22       There are authorized to be appropriated to the Sec-  
 23       retary such sums as may be necessary to contract  
 24       with Medicare Consumer Coalitions under this sec-  
 25       tion.

1           “(5) MEDICARE CONSUMER COALITION DE-  
 2           FINED.—In this subsection, the term ‘Medicare Con-  
 3           sumer Coalition’ means an entity that is a nonprofit  
 4           organization operated under the direction of a board  
 5           of directors that is primarily composed of bene-  
 6           ficiaries under this title.

7   “PREMIUMS

8           “SEC. 1860D. (a) ANNUAL ESTABLISHMENT OF  
 9           MONTHLY PREMIUM RATES.—

10           “(1) IN GENERAL.—The Secretary shall, during  
 11           September of each year (beginning in 2001), deter-  
 12           mine and promulgate a monthly premium rate for  
 13           the succeeding year in accordance with the provi-  
 14           sions of this subsection.

15           “(2) ACTUARIAL DETERMINATIONS.—

16           “(A) DETERMINATION OF ANNUAL BEN-  
 17           EFIT AND ADMINISTRATIVE COSTS.—The Sec-  
 18           retary shall estimate annually for the suc-  
 19           ceeding year the amount equal to the total of  
 20           the benefits and administrative costs that will  
 21           be payable from the Federal Supplementary  
 22           Medical Insurance Trust Fund for providing  
 23           covered outpatient drugs in such calendar year  
 24           with respect to enrollees in the program under  
 25           this part.

1                   “(B) DETERMINATION OF MONTHLY PRE-  
2                   MIUM RATES.—

3                   “(i) IN GENERAL.—The Secretary  
4                   shall determine the monthly premium rate  
5                   with respect to such enrollees for such suc-  
6                   ceeding year, which shall be  $\frac{1}{12}$  of the ap-  
7                   plicable share of the amount determined  
8                   under subparagraph (A), divided by the  
9                   total number of such enrollees, and round-  
10                  ed (if such rate is not a multiple of 10  
11                  cents) to the nearest multiple of 10 cents.

12                  “(ii) DEFINITION OF APPLICABLE  
13                  SHARE.—For purposes of clause (i), the  
14                  term ‘applicable share’ means—

15                         “(I) one-half, in the case of pre-  
16                         miums paid by an eligible beneficiary  
17                         enrolled in the program under this  
18                         part; and

19                         “(II) two-thirds, in the case of  
20                         premiums paid for such a beneficiary  
21                         by an employer (as defined in section  
22                         1860I(e)(2)) that the beneficiary for-  
23                         merly worked for.

24                  “(3) PUBLICATION OF ASSUMPTIONS.—The  
25                  Secretary shall publish, together with the promulga-

1       tion of the monthly premium rates for the suc-  
 2       ceeding year, a statement setting forth the actuarial  
 3       assumptions and bases employed in arriving at the  
 4       amounts and rates determined under paragraphs (1)  
 5       and (2).

6       “(b) COLLECTION OF PREMIUM.—The monthly pre-  
 7       mium applicable to an eligible beneficiary under this part  
 8       shall be collected and credited to the Federal Supple-  
 9       mentary Medical Insurance Trust Fund in the same man-  
 10      ner as the monthly premium determined under section  
 11      1839 is collected and credited to such Trust Fund under  
 12      section 1840.

13                               “COST-SHARING

14       “SEC. 1860E. (a) DEDUCTIBLE.—

15               “(1) IN GENERAL.—Subject to paragraph (2),  
 16       no payments shall be made under this part on behalf  
 17       of an eligible beneficiary until the beneficiary has  
 18       met a \$250 deductible.

19               “(2) WAIVER OF DEDUCTIBLE FOR GENERIC  
 20       DRUGS.—

21               “(A) IN GENERAL.—An eligible entity may  
 22       provide that generic drugs are not subject to  
 23       the deductible described in paragraph (1) if the  
 24       Secretary determines that the waiver of the  
 25       deductible—

1 “(i) is tied to the performance meas-  
 2 ures and other incentives applicable to the  
 3 entity pursuant to section 1860H(a); and

4 “(ii) will not result in an increase in  
 5 the expenditures made from the Federal  
 6 Supplementary Medical Insurance Trust  
 7 Fund.

8 “(B) CREDIT FOR AMOUNTS PAID.—If the  
 9 deductible is waived pursuant to subparagraph  
 10 (A), any coinsurance paid by an eligible bene-  
 11 ficiary for the generic drug shall be credited to-  
 12 ward the annual deductible.

13 “(b) COINSURANCE.—

14 “(1) ESTABLISHMENT.—

15 “(A) IN GENERAL.—Subject to paragraph  
 16 (2), if any covered outpatient drug is provided  
 17 to an eligible beneficiary in a year after the  
 18 beneficiary has met any deductible requirement  
 19 under subsection (a) for the year, the bene-  
 20 ficiary shall be responsible for making payments  
 21 for the drug in an amount equal to the applica-  
 22 ble percentage of the cost of the drug.

23 “(B) APPLICABLE PERCENTAGE DE-  
 24 FINED.—For purposes of subparagraph (A), the  
 25 ‘applicable percentage’ means, with respect to

1 any covered outpatient drug provided to an eli-  
2 gible beneficiary in a year—

3 “(i) 50 percent to the extent the out-  
4 of-pocket expenses of the beneficiary for  
5 such drug, when added to the out-of-pocket  
6 expenses of the beneficiary for covered out-  
7 patient drugs previously provided in the  
8 year, do not exceed \$3,500;

9 “(ii) 25 percent to the extent such ex-  
10 penses, when so added, exceed \$3,500 but  
11 do not exceed \$4,000; and

12 “(iii) 0 percent to the extent such ex-  
13 penses, when so added, would exceed  
14 \$4,000.

15 “(C) OUT-OF-POCKET EXPENSES DE-  
16 FINED.—For purposes of subparagraph (B),  
17 the term ‘out-of-pocket expenses’ means ex-  
18 penses incurred as a result of the application of  
19 the deductible under subsection (a) and the co-  
20 insurance required under this subsection.

21 “(2) REDUCTION BY ELIGIBLE ENTITY.—An el-  
22 igible entity may reduce the applicable percentage  
23 that an eligible beneficiary is subject to under para-  
24 graph (1) if the Secretary determines that such  
25 reduction—

7 “(c) INFLATION ADJUSTMENT.—

12 “(A) such dollar amount, multiplied by

18           “(2) ROUNDING.—If any dollar amount after  
19           being increased under paragraph (1) is not a mul-  
20           tiple of \$5, such dollar amount shall be rounded to  
21           the nearest multiple of \$5.

23 DRUG BENEFIT

**•S 3107 IS**



1           “(1) IN GENERAL.—The Secretary shall estab-  
2       lish procedures under which the Secretary accepts  
3       bids submitted by eligible entities and awards con-  
4       tracts to such entities in order to administer and de-  
5       liver the benefits provided under this part to eligible  
6       beneficiaries in an area.

7           “(2) COMPETITIVE PROCEDURES.—Competitive  
8       procedures (as defined in section 4(5) of the Office  
9       of Federal Procurement Policy Act (41 U.S.C.  
10      403(5))) shall be used to enter into contracts under  
11      this part.

12      “(b) AREA FOR CONTRACTS.—

13           “(1) REGIONAL BASIS.—

14           “(A) IN GENERAL.—Except as provided in  
15       subparagraph (B) and subject to paragraph (2),  
16       the contract entered into between the Secretary  
17       and an eligible entity shall require the eligible  
18       entity to provide covered outpatient drugs on a  
19       regional basis.

20           “(B) PARTIAL REGIONAL BASIS.—

21           “(i) IN GENERAL.—If determined ap-  
22       propriate by the Secretary, the Secretary  
23       may permit the coverage described in sub-  
24       paragraph (A) to be provided on a partial  
25       regional basis.

“(ii) REQUIREMENTS.—If the Secretary permits coverage pursuant to clause (i), the Secretary shall ensure that the partial region in which coverage is provided is—

“(I) at least the size of the commercial service area of the eligible entity for that area; and

“(II) not smaller than a State.

“(2) DETERMINATION.—

“(A) IN GENERAL.—In determining coverage areas under this part, the Secretary shall—

“(i) take into account the number of eligible beneficiaries in an area in order to encourage participation by eligible entities; and

“(ii) ensure that there are at least 10 different coverage areas in the United States.

“(B) NO ADMINISTRATIVE OR JUDICIAL REVIEW.—The determination of coverage areas under this part shall not be subject to administrative or judicial review.

“(c) SUBMISSION OF BIDS.—

1           “(1) IN GENERAL.—Each eligible entity desir-  
 2           ing to provide covered outpatient drugs under this  
 3           part shall submit a bid to the Secretary at such  
 4           time, in such manner, and accompanied by such in-  
 5           formation as the Secretary may reasonably require.

6           “(2) REQUIRED INFORMATION.—The bids de-  
 7           scribed in paragraph (1) shall include—

8                   “(A) a proposal for the estimated prices of  
 9                   covered outpatient drugs and the projected an-  
 10                  nual increases in such prices, including differen-  
 11                  tials between formulary and nonformulary  
 12                  prices, if applicable;

13                  “(B) the amount that the entity will  
 14                  charge the Secretary for administering and de-  
 15                  livering the benefits under such contract;

16                  “(C) a statement regarding whether the  
 17                  entity will waive the deductible for generic  
 18                  drugs pursuant to section 1860E(a)(2);

19                  “(D) a statement regarding whether the  
 20                  entity will reduce the applicable coinsurance  
 21                  percentage pursuant to section 1860E(b)(2)  
 22                  and if so, the amount of such reduction;

23                  “(E) a detailed description of—

24                          “(i) the risk corridors tied to perform-  
 25                          ance measures and other incentives that

1 the entity will accept under the contract;  
 2 and

3 “(ii) how the entity will meet such  
 4 measures and incentives;

5 “(F) a detailed description of any owner-  
 6 ship or shared financial interests with other en-  
 7 tities involved in the delivery of the benefit as  
 8 proposed;

9 “(G) a detailed description of the entity’s  
 10 estimated marketing and advertising expendi-  
 11 tures related to enrolling and retaining eligible  
 12 beneficiaries; and

13 “(H) such other information that the Sec-  
 14 retary determines is necessary in order to carry  
 15 out this part, including information relating to  
 16 the bidding process under this part.

17 “(d) ACCESS.—

18 “(1) IN GENERAL.—The Secretary shall ensure  
 19 that an eligible entity—

20 “(A) complies with the access requirements  
 21 described in section 1860G(4)(A); and

22 “(B) makes available to each beneficiary  
 23 covered under the contract the full scope of the  
 24 benefits required under this part.

1           “(2) AREAS NOT COVERED BY CONTRACTS.—

2           The Secretary shall develop procedures for the provi-  
3           sion of covered outpatient drugs under this part to  
4           each eligible beneficiary that resides in an area that  
5           is not covered by any contract under this part.

6           “(3) BENEFICIARIES RESIDING IN DIFFERENT

7           LOCATIONS.—The Secretary shall develop procedures  
8           to ensure that each eligible beneficiary that resides  
9           in different areas in a year is provided the benefits  
10          under this part throughout the entire year.

11          “(e) AWARDING OF CONTRACTS.—

12          “(1) NUMBER OF CONTRACTS.—The Secretary  
13          shall, consistent with the requirements of this part  
14          and the goal of containing costs under this title,  
15          award in a competitive manner at least 2 contracts  
16          in an area, unless only 1 bidding entity meets the  
17          minimum standards specified under this part and by  
18          the Secretary.

19          “(2) DETERMINATION.—In determining which  
20          of the eligible entities that submitted bids that meet  
21          the minimum standards specified under this part  
22          and by the Secretary (including the terms and condi-  
23          tions described in section 1860G) to award a con-  
24          tract, the Secretary shall consider the comparative  
25          merits of each bid, as determined on the basis of the

1 past performance of the entity and other relevant  
2 factors, with respect to—

3 “(A) how well the entity meets such min-  
4 imum standards;

5 “(B) the amount that the entity will  
6 charge the Secretary for administering and de-  
7 livering the benefits under the contract;

8 “(C) the proposed prices of covered out-  
9 patient drugs and annual increases in such  
10 prices;

11 “(D) the proposed risk corridors tied to  
12 performance measures and other incentives that  
13 the entity will be subject to under the contract;

14 “(E) the factors described in section  
15 1860C(b)(2);

16 “(F) prior experience in administering a  
17 prescription drug benefit program;

18 “(G) effectiveness in containing costs  
19 through pricing incentives and utilization man-  
20 agement; and

21 “(H) such other factors as the Secretary  
22 deems necessary to evaluate the merits of each  
23 bid.

24 “(3) EXCEPTION TO CONFLICT OF INTEREST  
25 RULES.—In awarding contracts under this part, the

1 Secretary may waive conflict of interest laws gen-  
2 erally applicable to Federal acquisitions (subject to  
3 such safeguards as the Secretary may find necessary  
4 to impose) in circumstances where the Secretary  
5 finds that such waiver—

6 “(A) is not inconsistent with the—

7 “(i) purposes of the programs under  
8 this title; or

9 “(ii) best interests of enrolled individ-  
10 uals; and

11 “(B) permits a sufficient level of competi-  
12 tion for such contracts, promotes efficiency of  
13 benefits administration, or otherwise serves the  
14 objectives of the program under this part.

15 “(4) NO ADMINISTRATIVE OR JUDICIAL RE-  
16 VIEW.—The determination of the Secretary to award  
17 or not award a contract to an eligible entity under  
18 this part shall not be subject to administrative or ju-  
19 dicial review.

20 “(f) APPROVAL OF MARKETING MATERIAL AND AP-  
21 PPLICATION FORMS.—The provisions of section 1851(h)  
22 shall apply to marketing material and application forms  
23 under this part in the same manner as such provisions  
24 apply to marketing material and application forms under  
25 part C.

1       “(g) DURATION OF CONTRACTS.—Each contract  
 2 under this part shall be for a term of at least 2 years  
 3 but not more than 5 years, as determined by the Sec-  
 4 retary.

5       “CONDITIONS FOR AWARDING CONTRACT

6       “SEC. 1860G. The Secretary shall not award a con-  
 7 tract to an eligible entity under this part unless the Sec-  
 8 retary finds that the eligible entity agrees to comply with  
 9 such terms and conditions as the Secretary shall specify,  
 10 including the following:

11       “(1) QUALITY AND FINANCIAL STANDARDS.—

12       The eligible entity meets the quality and financial  
 13 standards specified by the Secretary.

14       “(2) PROCEDURES TO ENSURE PROPER UTILI-  
 15 ZATION, COMPLIANCE, AND AVOIDANCE OF ADVERSE  
 16 DRUG REACTIONS.—The eligible entity has in place  
 17 drug utilization review procedures to ensure—

18       “(A) the appropriate utilization by eligible  
 19 beneficiaries of the benefits to be provided  
 20 under the contract; and

21       “(B) the avoidance of adverse drug reac-  
 22 tions among eligible beneficiaries enrolled with  
 23 the entity, including problems due to thera-  
 24 peutic duplication, drug-disease contraindica-  
 25 tions, drug-drug interactions (including serious  
 26 interactions with nonprescription or over-the-



1 counter drugs), incorrect drug dosage or dura-  
 2 tion of drug treatment, drug-allergy inter-  
 3 actions, and clinical abuse and misuse.

4 “(3) COST-EFFECTIVE PROVISION OF BENE-  
 5 FITS.—

6 “(A) IN GENERAL.—In providing the bene-  
 7 fits under a contract under this part, an eligible  
 8 entity may—

9 “(i) employ mechanisms to provide  
 10 the benefits economically, including the use  
 11 of—

12 “(I) formularies (pursuant to  
 13 subparagraph (B));

14 “(II) alternative methods of dis-  
 15 tribution; and

16 “(III) generic drug substitution;

17 “(ii) use mechanisms to encourage eli-  
 18 gible beneficiaries to select cost-effective  
 19 drugs or less costly means of receiving  
 20 drugs, including the use of pharmacy in-  
 21 centive programs, therapeutic interchange  
 22 programs, and disease management pro-  
 23 grams; and

24 “(iii) encourage pharmacy providers  
 25 to—

1 “(I) inform beneficiaries of the  
2 differentials in price between generic  
3 and nongeneric drug equivalents; and

4 “(II) provide medication therapy  
5 management programs in order to en-  
6 hance beneficiaries’ understanding of  
7 the appropriate use of medications  
8 and to reduce the risk of potential ad-  
9 verse events associated with medica-  
10 tions.

11 “(B) FORMULARIES.—If an eligible entity  
12 uses a formulary under this part, such for-  
13 mulary shall comply with standards established  
14 by the Secretary in consultation with the Medi-  
15 care Pharmacy and Therapeutics Advisory  
16 Committee established under section 1860M.  
17 Such standards shall require that the eligible  
18 entity—

19 “(i) use a pharmacy and therapeutic  
20 committee (that meets the standards for a  
21 pharmacy and therapeutic committee es-  
22 tablished by the Secretary in consultation  
23 with the Medicare Pharmacy and Thera-  
24 peutics Advisory Committee established

1 under section 1860M) to develop and im-  
2 plement the formulary;

3 “(ii) include in the formulary—

4 “(I) at least 1 drug from each  
5 therapeutic class (as defined by the  
6 entity’s pharmacy and therapeutic  
7 committee in accordance with stand-  
8 ards established by the Secretary in  
9 consultation with the Medicare Phar-  
10 macy and Therapeutics Advisory  
11 Committee established under section  
12 1860M);

13 “(II) if there is more than 1 drug  
14 available in a therapeutic class, at  
15 least 2 drugs from such class; and

16 “(III) if there is more than 2  
17 drugs available in a therapeutic class,  
18 at least 2 drugs from such class and  
19 a generic drug substitute if available;

20 “(iii) develop procedures for the—

21 “(I) addition of new therapeutic  
22 classes to the formulary;

23 “(II) addition of new drugs to an  
24 existing therapeutic class; and

1                   “(III) modification of the for-  
2                   mulary;

3                   “(iv) provide for coverage of nonfor-  
4                   mulary drugs when determined (pursuant  
5                   to subparagraph (C) or (D)(i) of para-  
6                   graph (4)) to be medically necessary to  
7                   prevent or slow the deterioration of, or im-  
8                   prove or maintain, the health of an eligible  
9                   beneficiary; and

10                  “(v) disclose to current and prospec-  
11                  tive beneficiaries and to providers in the  
12                  service area the nature of the formulary  
13                  restrictions, including information regard-  
14                  ing the drugs included in the formulary,  
15                  coinsurance, and any difference in the  
16                  cost-sharing for different types of drugs.

17                  “(C) CONSTRUCTION.—Nothing in this  
18                  paragraph shall be construed as precluding an  
19                  eligible entity from—

20                  “(i) requiring cost-sharing for nonfor-  
21                  mulary drugs that is higher than the cost-  
22                  sharing established in section 1860E(b),  
23                  except that such entity shall provide for  
24                  coverage of a nonformulary drug at the  
25                  same cost-sharing level as a drug within

the formulary if such nonformulary drug is determined (pursuant to subparagraph (C) or (D)(i) of paragraph (4)) to be medically necessary to prevent or slow the deterioration of, or improve or maintain, the health of an eligible beneficiary;

“(ii) educating prescribing providers, pharmacists, and beneficiaries about the medical and cost benefits of formulary drugs (including generic drugs); or

“(iii) requesting prescribing providers to consider a formulary drug prior to dispensing of a nonformulary drug, as long as such request does not unduly delay the provision of the drug.

“(4) PATIENT PROTECTIONS.—

“(A) ACCESS.—The eligible entity ensures that the covered outpatient drugs are accessible and convenient to eligible beneficiaries covered under the contract, including by offering the services in the following manner:

“(i) SERVICES DURING EMERGENCIES.—The offering of services 24 hours a day and 7 days a week for emergencies.

1 “(ii) CONTRACTS WITH RETAIL PHAR-  
2 MACIES.—The offering of services—

3 “(I) at a sufficient number (as  
4 determined by the Secretary) of retail  
5 pharmacies;

6 “(II) to the extent feasible, at re-  
7 tail pharmacies located throughout  
8 the eligible entity’s service area to en-  
9 sure reasonable geographic access (as  
10 determined by the Secretary) to such  
11 services; and

12 “(III) such that—

13 “(aa) the total charge for  
14 each covered outpatient drug dis-  
15 pensed to an eligible beneficiary  
16 enrolled with the entity does not  
17 exceed the negotiated price for  
18 the drug (as reported to the Sec-  
19 retary pursuant to paragraph  
20 (6)(A)); and

21 “(bb) the retail pharmacy  
22 dispensing the drug does not  
23 charge (or collect from) such  
24 beneficiary an amount that ex-  
25 ceeds the beneficiary’s obligation

1 (as determined in accordance  
2 with the provisions of this part)  
3 of the negotiated price.

4 “(B) CONTINUITY OF CARE.—

5 “(i) IN GENERAL.—The eligible entity  
6 ensures that, in the case of an eligible ben-  
7 eficiary who loses coverage under this part  
8 with such entity under circumstances that  
9 would permit a special election period (as  
10 established by the Secretary under section  
11 1860B(b)), the entity will continue to pro-  
12 vide coverage under this part to such bene-  
13 ficiary until the beneficiary enrolls and re-  
14 ceives such coverage with another eligible  
15 entity under this part.

16 “(ii) LIMITED PERIOD.—In no event  
17 shall an eligible entity be required to pro-  
18 vide the extended coverage required under  
19 clause (i) beyond the date which is 30 days  
20 after the coverage with such entity would  
21 have terminated but for this subparagraph.

22 “(C) PROCEDURES REGARDING THE DE-  
23 TERMINATION OF DRUGS THAT ARE MEDICALLY  
24 NECESSARY.—The eligible entity has in place  
25 procedures to determine if a drug is medically

1           necessary to prevent or slow the deterioration  
2           of, or improve or maintain, the health of an eli-  
3           gible beneficiary. Such procedures shall require  
4           that such determinations are based on profes-  
5           sional medical judgment, the medical condition  
6           of the beneficiary, and other medical evidence.

7           “(D) PROCEDURES REGARDING DENIALS  
8           OF CARE.—The eligible entity has in place pro-  
9           cedures to ensure—

10           “(i) a timely internal and external re-  
11           view and resolution of denials of coverage  
12           (in whole or in part) and complaints (in-  
13           cluding those regarding the use of  
14           formularies under paragraph (3)) by eligi-  
15           ble beneficiaries, or by providers, phar-  
16           macists, and other individuals acting on  
17           behalf of each such beneficiary (with the  
18           beneficiary’s consent) in accordance with  
19           requirements (as established by the Sec-  
20           retary) that are comparable to such re-  
21           quirements for Medicare+Choice organiza-  
22           tions under part C; and

23           “(ii) that beneficiaries are provided  
24           with information regarding the appeals



1           procedures under this part at the time of  
2           enrollment.

3           “(E) PROCEDURES REGARDING PATIENT  
4           CONFIDENTIALITY.—Insofar as an eligible enti-  
5           ty maintains individually identifiable medical  
6           records or other health information regarding  
7           eligible beneficiaries under a contract entered  
8           into under this part, the entity has in place pro-  
9           cedures to—

10               “(i) safeguard the privacy of any indi-  
11               vidually identifiable beneficiary informa-  
12               tion;

13               “(ii) maintain such records and infor-  
14               mation in a manner that is accurate and  
15               timely;

16               “(iii) ensure timely access by such  
17               beneficiaries to such records and informa-  
18               tion; and

19               “(iv) otherwise comply with applicable  
20               laws relating to patient confidentiality.

21           “(F) PROCEDURES REGARDING TRANSFER  
22           OF MEDICAL RECORDS.—

23               “(i) IN GENERAL.—The eligible entity  
24               has in place procedures for the timely  
25               transfer of records and information de-

scribed in subparagraph (E) (with respect to a beneficiary who loses coverage under this part with the entity and enrolls with another entity under this part) to such other entity.

“(ii) PATIENT CONFIDENTIALITY.—

The procedures described in clause (i) shall comply with the patient confidentiality procedures described in subparagraph (E).

“(G) PROCEDURES REGARDING MEDICAL

ERRORS.—The eligible entity has in place procedures for working with the Secretary to deter medical errors related to the provision of covered outpatient drugs.

“(5) PROCEDURES TO CONTROL FRAUD, ABUSE,

AND WASTE.—The eligible entity has in place procedures to control fraud, abuse, and waste.

“(6) REPORTING REQUIREMENTS.—

“(A) IN GENERAL.—The eligible entity provides the Secretary with reports containing information regarding the following:

“(i) The prices that the eligible entity is paying for covered outpatient drugs.

1           “(ii) The prices that eligible bene-  
 2           ficiaries enrolled with the entity will be  
 3           charged for covered outpatient drugs.

4           “(iii) The administrative costs of pro-  
 5           viding such benefits.

6           “(iv) Utilization of such benefits.

7           “(v) Marketing and advertising ex-  
 8           penditures related to enrolling and retain-  
 9           ing eligible beneficiaries.

10          “(B) TIMEFRAME FOR SUBMITTING RE-  
 11          PORTS.—

12           “(i) IN GENERAL.—The eligible entity  
 13           shall submit a report described in subpara-  
 14           graph (A) to the Secretary within 3  
 15           months after the end of each 12-month pe-  
 16           riod in which the eligible entity has a con-  
 17           tract under this part. Such report shall  
 18           contain information concerning the benefits  
 19           provided during such 12-month period.

20           “(ii) LAST YEAR OF CONTRACT.—In  
 21           the case of the last year of a contract  
 22           under this section, the Secretary may re-  
 23           quire that a report described in subpara-  
 24           graph (A) be submitted 3 months prior to  
 25           the end of the contract. Such report shall

1 contain information concerning the benefits  
2 provided between the period covered by the  
3 most recent report under this subpara-  
4 graph and the date that a report is sub-  
5 mitted under this clause.

6 “(C) CONFIDENTIALITY OF INFORMA-  
7 TION.—

8 “(i) IN GENERAL.—Notwithstanding  
9 any other provision of law and subject to  
10 clause (ii), information disclosed by an eli-  
11 gible entity pursuant to subparagraph (A)  
12 is confidential and shall only be used by  
13 the Secretary for the purposes of, and to  
14 the extent necessary, to carry out this  
15 part.

16 “(ii) UTILIZATION DATA.—Subject to  
17 patient confidentiality laws, the Secretary  
18 shall make information disclosed by an eli-  
19 gible entity pursuant to subparagraph  
20 (A)(iv) (regarding utilization data) avail-  
21 able for research purposes. The Secretary  
22 may charge a reasonable fee for making  
23 such information available.

24 “(7) APPROVAL OF MARKETING MATERIAL AND  
25 APPLICATION FORMS.—The eligible entity will com-

1       ply with the requirements described in section  
2       1860F(f).

3               “(8) RECORDS AND AUDITS.—The eligible enti-  
4       ty maintains adequate records related to the admin-  
5       istration of the benefit under this part and affords  
6       the Secretary access to such records for auditing  
7       purposes.

8                               “PAYMENTS

9       “SEC. 1860H. (a) PAYMENTS TO ELIGIBLE ENTI-  
10   TIES.—

11               “(1) PROCEDURES.—

12                       “(A) IN GENERAL.—The Secretary shall  
13       establish procedures for making payments to an  
14       eligible entity under a contract entered into  
15       under this part for the administration and de-  
16       livery of the benefits under this part.

17                       “(B) ENTITIES ONLY SUBJECT TO LIM-  
18       ITED RISK.—Under the procedures established  
19       under subparagraph (A), an eligible entity shall  
20       only be at risk to the extent that the entity is  
21       at risk under paragraph (2).

22               “(2) RISK CORRIDORS TIED TO PERFORMANCE  
23   MEASURES AND OTHER INCENTIVES.—

24                       “(A) IN GENERAL.—The procedures estab-  
25       lished under paragraph (1) may include the use  
26       of—

1 “(i) risk corridors tied to performance  
2 measures that have been agreed to between  
3 the eligible entity and the Secretary under  
4 the contract; and

5 “(ii) any other incentives that the  
6 Secretary determines appropriate.

7 “(B) PHASE-IN OF RISK CORRIDORS TIED  
8 TO PERFORMANCE MEASURES.—The Secretary  
9 may phase-in the use of risk corridors tied to  
10 performance measures if the Secretary deter-  
11 mines such phase-in to be appropriate.

12 “(C) PAYMENTS SUBJECT TO INCEN-  
13 TIVES.—If a contract under this part includes  
14 the use of risk corridors tied to performance  
15 measures or other incentives pursuant to sub-  
16 paragraph (A), payments to eligible entities  
17 under such contract shall be subject to such  
18 risk corridors tied to performance measures and  
19 other incentives.

20 “(3) RISK ADJUSTMENT.—To the extent that  
21 eligible entities are at risk because of the risk cor-  
22 ridors or other incentives described in paragraph  
23 (2)(A), the procedures established under paragraph  
24 (1) may include a methodology for adjusting the  
25 payments made to such entities based on the dif-

1       ferences in actuarial risk of different enrollees being  
 2       served if the Secretary determines such adjustments  
 3       to be necessary and appropriate.

4       “(b) SECONDARY PAYER PROVISIONS.—The provi-  
 5       sions of section 1862(b) shall apply to the benefits pro-  
 6       vided under this part.

7       “EMPLOYER INCENTIVE PROGRAM FOR EMPLOYMENT-  
 8               BASED RETIREE DRUG COVERAGE

9       “SEC. 1860I. (a) PROGRAM AUTHORITY.—The Sec-  
 10       retary is authorized to develop and implement a program  
 11       under this section called the ‘Employer Incentive Pro-  
 12       gram’ that encourages employers and other sponsors of  
 13       employment-based health care coverage to provide ade-  
 14       quate prescription drug benefits to retired individuals by  
 15       subsidizing, in part, the sponsor’s cost of providing cov-  
 16       erage under qualifying plans.

17       “(b) SPONSOR REQUIREMENTS.—In order to be eligi-  
 18       ble to receive an incentive payment under this section with  
 19       respect to coverage of an individual under a qualified re-  
 20       tiree prescription drug plan (as defined in subsection  
 21       (f)(3)), a sponsor shall meet the following requirements:

22               “(1) ASSURANCES.—The sponsor shall—

23                       “(A) annually attest, and provide such as-  
 24                       surances as the Secretary may require, that the  
 25                       coverage offered by the sponsor is a qualified  
 26                       retiree prescription drug plan, and will remain

1           such a plan for the duration of the sponsor's  
2           participation in the program under this section;  
3           and

4           “(B) guarantee that it will give notice to  
5           the Secretary and covered retirees—

6           “(i) at least 120 days before termi-  
7           nating its plan; and

8           “(ii) immediately upon determining  
9           that the actuarial value of the prescription  
10          drug benefit under the plan falls below the  
11          actuarial value of the outpatient prescrip-  
12          tion drug benefit under this part.

13          “(2) BENEFICIARY INFORMATION.—The spon-  
14          sor shall report to the Secretary, for each calendar  
15          quarter for which it seeks an incentive payment  
16          under this section, the names and social security  
17          numbers of all retirees (and their spouses and de-  
18          pendents) covered under such plan during such  
19          quarter and the dates (if less than the full quarter)  
20          during which each such individual was covered.

21          “(3) AUDITS.—The sponsor and the employ-  
22          ment-based retiree health coverage plan seeking in-  
23          centive payments under this section shall agree to  
24          maintain, and to afford the Secretary access to, such  
25          records as the Secretary may require for purposes of



audits and other oversight activities necessary to ensure the adequacy of prescription drug coverage, the accuracy of incentive payments made, and such other matters as may be appropriate.

“(4) OTHER REQUIREMENTS.—The sponsor shall provide such other information, and comply with such other requirements, as the Secretary may find necessary to administer the program under this section.

“(c) INCENTIVE PAYMENTS.—

“(1) IN GENERAL.—A sponsor that meets the requirements of subsection (b) with respect to a quarter in a calendar year shall be entitled to have payment made by the Secretary on a quarterly basis (to the sponsor or, at the sponsor’s direction, to the appropriate employment-based health plan) of an incentive payment, in the amount determined in paragraph (2), for each retired individual (or spouse) who—

“(A) was covered under the sponsor’s qualified retiree prescription drug plan during such quarter; and

“(B) was eligible for but was not enrolled in the outpatient prescription drug benefit program under this part.

1           “(2) AMOUNT OF INCENTIVE.—The payment  
2           under this section with respect to each individual de-  
3           scribed in paragraph (1) for a month shall be equal  
4           to  $\frac{2}{3}$  of the monthly premium amount payable by an  
5           eligible beneficiary enrolled under this part, as set  
6           for the calendar year pursuant to section  
7           1860D(a)(2).

8           “(3) PAYMENT DATE.—The incentive under  
9           this section with respect to a calendar quarter shall  
10          be payable as of the end of the next succeeding cal-  
11          endar quarter.

12          “(d) CIVIL MONEY PENALTIES.—A sponsor, health  
13          plan, or other entity that the Secretary determines has,  
14          directly or through its agent, provided information in con-  
15          nection with a request for an incentive payment under this  
16          section that the entity knew or should have known to be  
17          false shall be subject to a civil monetary penalty in an  
18          amount up to 3 times the total incentive amounts under  
19          subsection (c) that were paid (or would have been payable)  
20          on the basis of such information.

21          “(e) DEFINITIONS.—In this section:

22               “(1) EMPLOYMENT-BASED RETIREE HEALTH  
23               COVERAGE.—The term ‘employment-based retiree  
24               health coverage’ means health insurance or other  
25               coverage of health care costs for retired individuals

1 (or for such individuals and their spouses and de-  
2 pendents) based on their status as former employees  
3 or labor union members.

4 “(2) EMPLOYER.—The term ‘employer’ has the  
5 meaning given the term in section 3(5) of the Em-  
6 ployee Retirement Income Security Act of 1974 (ex-  
7 cept that such term shall include only employers of  
8 2 or more employees).

9 “(3) QUALIFIED RETIREE PRESCRIPTION DRUG  
10 PLAN.—The term ‘qualified retiree prescription drug  
11 plan’ means health insurance coverage included in  
12 employment-based retiree health coverage that—

13 “(A) provides coverage of the cost of pre-  
14 scription drugs whose actuarial value (as de-  
15 fined by the Secretary) to each retired bene-  
16 ficiary equals or exceeds the actuarial value of  
17 the benefits provided to an individual enrolled  
18 in the outpatient prescription drug benefit pro-  
19 gram under this part; and

20 “(B) does not deny, limit, or condition the  
21 coverage or provision of prescription drug bene-  
22 fits for retired individuals based on age or any  
23 health status-related factor described in section  
24 2702(a)(1) of the Public Health Service Act.

1           “(4) SPONSOR.—The term ‘sponsor’ has the  
2           meaning given the term ‘plan sponsor’ in section  
3           3(16)(B) of the Employer Retirement Income Secu-  
4           rity Act of 1974.

5           “(f) AUTHORIZATION OF APPROPRIATIONS.—There  
6           are authorized to be appropriated from time to time, out  
7           of any moneys in the Treasury not otherwise appropriated,  
8           such sums as may be necessary to carry out the program  
9           under this section.

10                               “APPROPRIATIONS

11           “SEC. 1860J. There are authorized to be appro-  
12           priated from time to time, out of any moneys in the Treas-  
13           ury not otherwise appropriated, to the Federal Supple-  
14           mentary Medical Insurance Trust Fund established under  
15           section 1841, an amount equal to the amount by which  
16           the benefits and administrative costs of providing the ben-  
17           efits under this part exceed the premiums collected under  
18           section 1860D.

19                               “SUBPART 2—MEDICARE PHARMACY AND  
20           THERAPEUTICS (P&T) ADVISORY COMMITTEE

21           “MEDICARE PHARMACY AND THERAPEUTICS (P&T)  
22                               ADVISORY COMMITTEE

23           “SEC. 1860M. (a) ESTABLISHMENT OF COM-  
24           MITTEE.—There is established a Medicare Pharmacy and  
25           Therapeutics Advisory Committee (in this section referred  
26           to as the ‘Committee’).

1       “(b) FUNCTIONS OF COMMITTEE.—On and after  
2 January 1, 2001, the Committee shall advise the Sec-  
3 retary on policies related to—

4           “(1) the development of guidelines for the im-  
5 plementation and administration of the outpatient  
6 prescription drug benefit program under this part;  
7 and

8           “(2) the development of—

9           “(A) standards for a pharmacy and thera-  
10 peutics committee required of eligible entities  
11 under section 1860G(3)(B)(i);

12           “(B) procedures required of eligible enti-  
13 ties under subparagraphs (C) and (D) of sec-  
14 tion 1860G(4) for determining if a drug is  
15 medically necessary to prevent or slow the dete-  
16 rioration of, or improve or maintain, the health  
17 of an eligible beneficiary;

18           “(C) standards for—

19           “(i) defining therapeutic classes;

20           “(ii) adding new therapeutic classes to  
21 a formulary;

22           “(iii) adding new drugs to a thera-  
23 peutic class within a formulary; and

24           “(iv) when and how often a formulary  
25 should be modified;

1           “(D) procedures to evaluate the bids sub-  
2           mitted by eligible entities under this part; and

3           “(E) procedures to ensure that eligible en-  
4           tities with a contract under this part are in  
5           compliance with the requirements under this  
6           part.

7           “(c) STRUCTURE AND MEMBERSHIP OF THE COM-  
8           MITTEE.—

9           “(1) STRUCTURE.—The Committee shall be  
10          composed of 19 members who shall be appointed by  
11          the Secretary.

12          “(2) MEMBERSHIP.—

13               “(A) IN GENERAL.—The members of the  
14               Committee shall be chosen on the basis of their  
15               integrity, impartiality, and good judgment, and  
16               shall be individuals who are, by reason of their  
17               education, experience, and attainments, excep-  
18               tionally qualified to perform the duties of mem-  
19               bers of the Committee.

20               “(B) SPECIFIC MEMBERS.—Of the mem-  
21               bers appointed under paragraph (1)—

22                       “(i) eleven shall be chosen to rep-  
23                       resent physicians;

24                       “(ii) four shall be chosen to represent  
25                       pharmacists;

1 “(iii) one shall be chosen to represent  
2 the Health Care Financing Administration;

3 “(iv) two shall be chosen to represent  
4 actuaries and pharmacoeconomists; and

5 “(v) one shall be chosen to represent  
6 emerging drug technologies.

7 “(d) TERMS OF APPOINTMENT.—Each member of  
8 the Committee shall serve for a term determined appro-  
9 priate by the Secretary. The terms of service of the mem-  
10 bers initially appointed shall begin on January 1, 2001.

11 “(e) CHAIRMAN.—The Secretary shall designate a  
12 member of the Committee as Chairman. The term as  
13 Chairman shall be for a 1-year period.

14 “(f) COMPENSATION AND TRAVEL EXPENSES.—

15 “(1) COMPENSATION OF MEMBERS.—Each  
16 member of the Committee who is not an officer or  
17 employee of the Federal Government shall be com-  
18 pensated at a rate equal to the daily equivalent of  
19 the annual rate of basic pay prescribed for level IV  
20 of the Executive Schedule under section 5315 of title  
21 5, United States Code, for each day (including travel  
22 time) during which such member is engaged in the  
23 performance of the duties of the Committee. All  
24 members of the Committee who are officers or em-  
25 ployees of the United States shall serve without com-

1       pensation in addition to that received for their serv-  
2       ices as officers or employees of the United States.

3           “(2) TRAVEL EXPENSES.—The members of the  
4       Committee shall be allowed travel expenses, includ-  
5       ing per diem in lieu of subsistence, at rates author-  
6       ized for employees of agencies under subchapter I of  
7       chapter 57 of title 5, United States Code, while  
8       away from their homes or regular places of business  
9       in the performance of services for the Committee.

10       “(g) OPERATION OF THE COMMITTEE.—

11           “(1) MEETINGS.—The Committee shall meet at  
12       the call of the Chairman (after consultation with the  
13       other members of the Committee) not less often  
14       than quarterly to consider a specific agenda of  
15       issues, as determined by the Chairman after such  
16       consultation.

17           “(2) QUORUM.—Ten members of the Com-  
18       mittee shall constitute a quorum for purposes of  
19       conducting business.

20       “(h) FEDERAL ADVISORY COMMITTEE ACT.—Section  
21       14 of the Federal Advisory Committee Act (5 U.S.C.  
22       App.) shall not apply to the Committee.

23       “(i) TRANSFER OF PERSONNEL, RESOURCES, AND  
24       ASSETS.—For purposes of carrying out its duties, the Sec-  
25       retary and the Committee may provide for the transfer



1 to the Committee of such civil service personnel in the em-  
 2 ploy of the Department of Health and Human Services,  
 3 and such resources and assets of the Department used in  
 4 carrying out this title, as the Committee requires.

5 “(j) AUTHORIZATION OF APPROPRIATIONS.—There  
 6 are authorized to be appropriated such sums as may be  
 7 necessary to carry out the purposes of this section.”.

8 (b) EXCLUSIONS FROM COVERAGE.—

9 (1) APPLICATION TO PART D.—Section 1862(a)  
 10 of the Social Security Act (42 U.S.C. 1395y(a)) is  
 11 amended in the matter preceding paragraph (1) by  
 12 striking “part A or part B” and inserting “part A,  
 13 B, or D”.

14 (2) PRESCRIPTION DRUGS NOT EXCLUDED  
 15 FROM COVERAGE IF REASONABLE AND NEC-  
 16 ESSARY.—Section 1862(a)(1) of the Social Security  
 17 Act (42 U.S.C. 1395y(a)(1)) is amended—

18 (A) in subparagraph (H), by striking  
 19 “and” at the end;

20 (B) in subparagraph (I), by striking the  
 21 semicolon at the end and inserting “, and”; and

22 (C) by adding at the end the following new  
 23 subparagraph:

24 “(J) in the case of prescription drugs cov-  
 25 ered under part D, which are not reasonable

1           and necessary to prevent or slow the deteriora-  
 2           tion of, or improve or maintain, the health of  
 3           eligible beneficiaries;”.

4           (c) CONFORMING REFERENCES TO PREVIOUS PART  
 5 D.—

6           (1) IN GENERAL.—Any reference in law (in ef-  
 7           fect before the date of enactment of this Act) to part  
 8           D of title XVIII of the Social Security Act is deemed  
 9           a reference to part E of such title (as in effect after  
 10          such date).

11          (2) SECRETARIAL SUBMISSION OF LEGISLATIVE  
 12          PROPOSAL.—Not later than 6 months after the date  
 13          of enactment of this Act, the Secretary of Health  
 14          and Human Services shall submit to the appropriate  
 15          committees of Congress a legislative proposal pro-  
 16          viding for such technical and conforming amend-  
 17          ments in the law as are required by the provisions  
 18          of this Act.

19 **SEC. 3. PART D BENEFITS UNDER MEDICARE+CHOICE**  
 20 **PLANS.**

21          (a) ELIGIBILITY, ELECTION, AND ENROLLMENT.—  
 22          Section 1851 of the Social Security Act (42 U.S.C.  
 23          1395w-21) is amended—

24               (1) in subsection (a)(1)(A), by striking “parts  
 25          A and B” and inserting “parts A, B, and D”; and

1           (2) in subsection (i)(1), by striking “parts A  
2           and B” and inserting “parts A, B, and D”.

3           (b) VOLUNTARY BENEFICIARY ENROLLMENT FOR  
4 DRUG COVERAGE.—Section 1852(a)(1)(A) of such Act  
5 (42 U.S.C. 1395w–22(a)(1)(A)) is amended by inserting  
6 “(and under part D to individuals also enrolled under that  
7 part)” after “parts A and B”.

8           (c) ACCESS TO SERVICES.—Section 1852(d)(1) of  
9 such Act (42 U.S.C. 1395w–22(d)(1)) is amended—

10           (1) in subparagraph (D), by striking “and” at  
11           the end;

12           (2) in subparagraph (E), by striking the period  
13           at the end and inserting “; and”; and

14           (3) by adding at the end the following new sub-  
15           paragraph:

16           “(F) in the case of covered outpatient  
17           drugs provided to individuals enrolled under  
18           part D (as defined in section 1860(1)), the or-  
19           ganization complies with the access require-  
20           ments applicable under part D.”.

21           (d) PAYMENTS TO ORGANIZATIONS.—Section  
22 1853(a)(1)(A) of such Act (42 U.S.C. 1395w–  
23 23(a)(1)(A)) is amended—

24           (1) by inserting “determined separately for the  
25           benefits under parts A and B and under part D (for

1 individuals enrolled under that part)” after “as cal-  
 2 culated under subsection (c)”;

3 (2) by striking “that area, adjusted for such  
 4 risk factors” and inserting “that area. In the case  
 5 of payment for the benefits under parts A and B,  
 6 such payment shall be adjusted for such risk factors  
 7 as”; and

8 (3) by inserting before the last sentence the fol-  
 9 lowing: “In the case of the payments for the benefits  
 10 under part D, such payment shall initially be ad-  
 11 justed for the risk factors of each enrollee as the  
 12 Secretary determines to be feasible and appropriate  
 13 to ensure actuarial equivalence. By 2005, the adjust-  
 14 ments to payments for benefits under part D shall  
 15 be for the same risk factors used to adjust payments  
 16 for the benefits under parts A and B.”.

17 (e) CALCULATION OF ANNUAL MEDICARE+CHOICE  
 18 CAPITATION RATES.—Section 1853(c) of such Act (42  
 19 U.S.C. 1395w–23(c)) is amended—

20 (1) in paragraph (1), in the matter preceding  
 21 subparagraph (A), by inserting “for benefits under  
 22 parts A and B” after “capitation rate”; and

23 (2) by adding at the end the following new  
 24 paragraph:

1           “(8) PAYMENT FOR PART D BENEFITS.—The  
2       Secretary shall determine a capitation rate for part  
3       D benefits (for individuals enrolled under such part)  
4       as follows:

5           “(A) DRUGS DISPENSED IN 2002.—In the  
6       case of prescription drugs dispensed in 2002,  
7       the capitation rate shall be based on the pro-  
8       jected national per capita costs for prescription  
9       drug benefits under part D and associated  
10      claims processing costs for beneficiaries enrolled  
11      under part D and not enrolled with a  
12      Medicare+Choice organization under this part.

13          “(B) DRUGS DISPENSED IN SUBSEQUENT  
14      YEARS.—In the case of prescription drugs dis-  
15      pensed in a subsequent year, the capitation rate  
16      shall be equal to the capitation rate for the pre-  
17      ceding year increased by the Secretary’s esti-  
18      mate of the projected per capita rate of growth  
19      in expenditures under this title for an individual  
20      enrolled under part D for such subsequent  
21      year.”.

22          (f) LIMITATION ON ENROLLEE LIABILITY.—Section  
23      1854(e) of such Act (42 U.S.C. 1395w–24(e)) is amended  
24      by adding at the end the following new paragraph:

1 “(5) SPECIAL RULE FOR PART D BENEFITS.—

2 With respect to outpatient prescription drug benefits  
 3 under part D, a Medicare+Choice organization may  
 4 not require that an enrollee pay a deductible or a co-  
 5 insurance percentage that exceeds the deductible or  
 6 coinsurance percentage applicable for such benefits  
 7 for an eligible beneficiary under part D.”.

8 (g) REQUIREMENT FOR ADDITIONAL BENEFITS.—

9 Section 1854(f)(1) of such Act (42 U.S.C. 1395w-  
 10 24(f)(1)) is amended by adding at the end the following  
 11 new sentence: “Such determination shall be made sepa-  
 12 rately for the benefits under parts A and B and for pre-  
 13 scription drug benefits under part D.”.

14 (h) EFFECTIVE DATE.—The amendments made by  
 15 this section shall apply to items and services provided  
 16 under a Medicare+Choice plan on or after January 1,  
 17 2002.

18 **SEC. 4. EXCLUSION OF PART D COSTS FROM DETERMINA-**  
 19 **TION OF PART B MONTHLY PREMIUM.**

20 Section 1839(g) of the Social Security Act (42 U.S.C.  
 21 1395r(g)) is amended—

22 (1) by striking “attributable to the application  
 23 of section” and inserting “attributable to—

24 “(1) the application of section”;

1           (2) by striking the period and inserting “;  
2           and”; and

3           (3) by adding at the end the following new  
4           paragraph:

5           “(2) the program under part D providing pay-  
6           ment for covered outpatient drugs (including costs  
7           associated with making payments to employers and  
8           other sponsors of employment-based health care cov-  
9           erage under the Employer Incentive Program under  
10          section 1860I).”.

11 **SEC. 5. ADDITIONAL ASSISTANCE FOR LOW-INCOME BENE-**  
12 **FICIARIES.**

13          (a) INCLUSION IN MEDICARE COST-SHARING.—Sec-  
14 tion 1905(p)(3) of the Social Security Act (42 U.S.C.  
15 1396d(p)(3)) is amended—

16           (1) in subparagraph (A)—

17                   (A) in clause (i), by striking “and” at the  
18           end;

19                   (B) in clause (ii), by inserting “and” at  
20           the end; and

21                   (C) by adding at the end the following new  
22           clause:

23                   “(iii) premiums under section 1860D.”;

1           (2) in subparagraph (B), by striking “section  
2   1813” and inserting “sections 1813 and 1860E(b)”;  
3   and

4           (3) in subparagraph (C), by striking “section  
5   1813 and section 1833(b)” and inserting “sections  
6   1813, 1833(b), and 1860E(a)”.

7           (b) EXPANSION OF MEDICAL ASSISTANCE.—Section  
8   1902(a)(10)(E) of the Social Security Act (42 U.S.C.  
9   1396a(a)(10)(E)) is amended—

10          (1) in clause (iii)—

11               (A) by striking “section 1905(p)(3)(A)(ii)”  
12               and inserting “clauses (ii) and (iii) of section  
13               1905(p)(3)(A), for the coinsurance described in  
14               section 1860E(b), and for the deductible de-  
15               scribed in section 1860E(a)”;

16               (B) by striking “and” at the end;

17          (2) by redesignating clause (iv) as clause (vi);  
18   and

19          (3) by inserting after clause (iii) the following  
20   new clauses:

21               “(iv) for making medical assistance avail-  
22               able for Medicare cost-sharing described in sec-  
23               tion 1905(p)(3)(A)(iii), for the coinsurance de-  
24               scribed in section 1860E(b), and for the de-  
25               ductible described in section 1860E(a) for indi-



1           viduals who would be qualified Medicare bene-  
 2           ficiaries described in section 1905(p)(1) but for  
 3           the fact that their income exceeds 120 percent  
 4           but does not exceed 135 percent of such official  
 5           poverty line for a family of the size involved;  
 6           “(v) for making medical assistance avail-  
 7           able for Medicare cost-sharing described in sec-  
 8           tion 1905(p)(3)(A)(iii) on a linear sliding scale  
 9           based on the income of such individuals for in-  
 10          dividuals who would be qualified Medicare bene-  
 11          ficiaries described in section 1905(p)(1) but for  
 12          the fact that their income exceeds 135 percent  
 13          but does not exceed 175 percent of such official  
 14          poverty line for a family of the size involved;  
 15          and”.

16          (c) NONAPPLICABILITY OF PAYMENT DIFFERENTIAL  
 17          REQUIREMENTS TO MEDICARE PART D COST-SHAR-  
 18          ING.—Section 1902(n)(2) of the Social Security Act (42  
 19          U.S.C. 1396a(n)(2)) is amended by adding at the end the  
 20          following new sentence: “The preceding sentence shall not  
 21          apply to coinsurance described in section 1860E(b) or  
 22          deductibles described in section 1860E(a).”.

23          (d) 100 PERCENT FEDERAL MEDICAL ASSISTANCE  
 24          PERCENTAGE.—The first sentence of section 1905(b) of

1 the Social Security Act (42 U.S.C. 1396d(b)) is  
2 amended—

3 (1) by striking “and” before “(3)”; and

4 (2) by inserting before the period at the end the  
5 following: “, and (4) the Federal medical assistance  
6 percentage shall be 100 percent with respect to med-  
7 ical assistance provided under clauses (iv) and (v) of  
8 section 1902(a)(10)(E)”.

9 (e) TREATMENT OF TERRITORIES.—Section 1108(g)  
10 of such Act (42 U.S.C. 1308(g)) is amended by adding  
11 at the end the following new paragraph:

12 “(3) Notwithstanding the preceding provisions of this  
13 subsection, with respect to fiscal year 2002 and any fiscal  
14 year thereafter, the amount otherwise determined under  
15 this subsection (and subsection (f)) for the fiscal year for  
16 a Commonwealth or territory shall be increased by the  
17 ratio (as estimated by the Secretary) of—

18 “(A) the aggregate amount of payments made  
19 to the 50 States and the District of Columbia for  
20 the fiscal year under title XIX that are attributable  
21 to making medical assistance available for individ-  
22 uals described in clauses (i), (iii), (iv), and (v) of  
23 section 1902(a)(10)(E) for payment of Medicare  
24 cost-sharing that consists of premiums under section

1       1860D, coinsurance described in section 1860E(b),  
 2       or deductibles described in section 1860E(a); to

3           “(B) the aggregate amount of total payments  
 4       made to such States and District for the fiscal year  
 5       under such title.”.

6       (f) CONFORMING AMENDMENTS.—Section 1933 of  
 7       the Social Security Act (42 U.S.C. 1396u–3) is  
 8       amended—

9           (1) in subsection (a), by striking “section  
 10       1902(a)(10)(E)(iv)” and inserting “section  
 11       1902(a)(10)(E)(vi)”;

12          (2) in subsection (c)(2)(A)—

13           (A) in clause (i), by striking “section  
 14       1902(a)(10)(E)(iv)(I)” and inserting “section  
 15       1902(a)(10)(E)(vi)(I)”;

16           (B) in clause (ii), by striking “section  
 17       1902(a)(10)(E)(iv)(II)” and inserting “section  
 18       1902(a)(10)(E)(vi)(II)”;

19          (3) in subsection (d), by striking “section  
 20       1902(a)(10)(E)(iv)” and inserting “section  
 21       1902(a)(10)(E)(vi)”;

22          (4) in subsection (e), by striking “section  
 23       1902(a)(10)(E)(iv)” and inserting “section  
 24       1902(a)(10)(E)(vi)”.

1       (g) **EFFECTIVE DATE.**—The amendments made by  
 2 this section shall apply for medical assistance provided  
 3 under section 1902(a)(10)(E) of the Social Security Act  
 4 (42 U.S.C. 1396a(a)(10)(E)) on and after January 1,  
 5 2002.

6 **SEC. 6. MEDIGAP REVISIONS.**

7       Section 1882 of the Social Security Act (42 U.S.C.  
 8 1395ss) is amended by adding at the end the following  
 9 new subsection:

10       “(v) **MODERNIZED BENEFIT PACKAGES FOR MEDI-**  
 11 **CARE SUPPLEMENTAL POLICIES.**—

12               “(1) **PROMULGATION OF MODEL REGULA-**  
 13 **TION.**—

14               “(A) **NAIC MODEL REGULATION.**—If,  
 15       within 9 months after the date of enactment of  
 16       the Medicare Outpatient Drug Act of 2000, the  
 17       National Association of Insurance Commis-  
 18       sioners (in this subsection referred to as the  
 19       ‘NAIC’) changes the 1991 NAIC Model Regula-  
 20       tion (described in subsection (p)) to revise the  
 21       benefit packages classified as ‘H’, ‘I’, and ‘J’  
 22       under the standards established by subsection  
 23       (p)(2) (including the benefit package classified  
 24       as ‘J’ with a high deductible feature, as de-  
 25       scribed in subsection (p)(11)) so that—

1           “(i) the coverage for outpatient pre-  
2           scription drugs available under such ben-  
3           efit packages is replaced with coverage for  
4           outpatient prescription drugs that com-  
5           pliments but does not duplicate the bene-  
6           fits for outpatient prescription drugs that  
7           beneficiaries are otherwise entitled to  
8           under this title;

9           “(ii) the revised benefit packages pro-  
10          vide a range of coverage options for out-  
11          patient prescription drugs for beneficiaries,  
12          but do not provide coverage for—

13                 “(I) the deductible under section  
14                 1860E(a); or

15                 “(II) more than 90 percent of  
16                 the coinsurance applicable to an indi-  
17                 vidual under section 1860E(b);

18           “(iii) uniform language and defini-  
19          tions are used with respect to such revised  
20          benefits;

21           “(iv) uniform format is used in the  
22          policy with respect to such revised benefits;  
23          and

1 “(v) such revised standards meet any  
2 additional requirements imposed by the  
3 Medicare Outpatient Drug Act of 2000;  
4 subsection (g)(2)(A) shall be applied in each  
5 State, effective for policies issued to policy hold-  
6 ers on and after January 1, 2002, as if the ref-  
7 erence to the Model Regulation adopted on  
8 June 6, 1979, were a reference to the 1991  
9 NAIC Model Regulation as changed under this  
10 subparagraph (such changed regulation referred  
11 to in this section as the ‘2002 NAIC Model  
12 Regulation’).

13 “(B) REGULATION BY THE SECRETARY.—  
14 If the NAIC does not make the changes in the  
15 1991 NAIC Model Regulation within the 9-  
16 month period specified in subparagraph (A), the  
17 Secretary shall promulgate, not later than 9  
18 months after the end of such period, a regula-  
19 tion and subsection (g)(2)(A) shall be applied in  
20 each State, effective for policies issued to policy  
21 holders on and after January 1, 2002, as if the  
22 reference to the Model Regulation adopted on  
23 June 6, 1979, were a reference to the 1991  
24 NAIC Model Regulation as changed by the Sec-  
25 retary under this subparagraph (such changed

1 regulation referred to in this section as the  
2 ‘2002 Federal Regulation’).

3 “(C) CONSULTATION WITH WORKING  
4 GROUP.—In promulgating standards under this  
5 paragraph, the NAIC or Secretary shall consult  
6 with a working group similar to the working  
7 group described in subsection (p)(1)(D).

8 “(D) MODIFICATION OF STANDARDS IF  
9 MEDICARE BENEFITS CHANGE.—If benefits (in-  
10 cluding deductibles and coinsurance) under part  
11 D of this title are changed and the Secretary  
12 determines, in consultation with the NAIC, that  
13 changes in the 2002 NAIC Model Regulation or  
14 2002 Federal Regulation are needed to reflect  
15 such changes, the preceding provisions of this  
16 paragraph shall apply to the modification of  
17 standards previously established in the same  
18 manner as they applied to the original estab-  
19 lishment of such standards.

20 “(2) CONSTRUCTION OF BENEFITS IN OTHER  
21 MEDICARE SUPPLEMENTAL POLICIES.—Nothing in  
22 the benefit packages classified as ‘A’ through ‘G’  
23 under the standards established by subsection (p)(2)  
24 (including the benefit package classified as ‘F’ with  
25 a high deductible feature, as described in subsection

1 (p)(11)) shall be construed as providing coverage for  
2 benefits for which payment may be made under part  
3 D.

4 “(3) APPLICATION OF PROVISIONS AND CON-  
5 FORMING REFERENCES.—

6 “(A) APPLICATION OF PROVISIONS.—The  
7 provisions of paragraphs (4) through (10) of  
8 subsection (p) shall apply under this section,  
9 except that—

10 “(i) any reference to the model regu-  
11 lation applicable under that subsection  
12 shall be deemed to be a reference to the  
13 applicable 2002 NAIC Model Regulation or  
14 2002 Federal Regulation; and

15 “(ii) any reference to a date under  
16 such paragraphs of subsection (p) shall be  
17 deemed to be a reference to the appro-  
18 priate date under this subsection.

19 “(B) OTHER REFERENCES.—Any reference  
20 to a provision of subsection (p) or a date appli-  
21 cable under such subsection shall also be con-  
22 sidered to be a reference to the appropriate pro-  
23 vision or date under this subsection.”.



1 **SEC. 7. HHS STUDIES AND REPORT TO CONGRESS.**

2 (a) STUDIES.—The Secretary of Health and Human  
3 Services shall conduct a study to determine the feasibility  
4 and advisability of—

5 (1) establishing a uniform format for pharmacy  
6 benefit cards provided to beneficiaries by eligible en-  
7 tities under the outpatient prescription drug benefit  
8 program under part D of title XVIII of the Social  
9 Security Act (as added by section 2); and

10 (2) developing systems to electronically transfer  
11 prescriptions under such program from the pre-  
12 scriber to the pharmacist.

13 (b) REPORT.—Not later than 2 years after the date  
14 of enactment of this Act, the Secretary of Health and  
15 Human Services shall submit to Congress a report on the  
16 results of the studies conducted under subsection (a), to-  
17 gether with any recommendations for legislation that the  
18 Secretary determines to be appropriate as a result of such  
19 studies.

20 **SEC. 8. APPROPRIATIONS.**

21 In addition to amounts otherwise appropriated to the  
22 Secretary of Health and Human Services, there are au-  
23 thorized to be appropriated to the Secretary for fiscal year  
24 2001 and each subsequent fiscal year such sums as may  
25 be necessary to administer the outpatient prescription

- 1 drug benefit program under part D of title XVIII of the
- 2 Social Security Act (as added by section 2).

